文献速递胸部肿瘤放疗

每日两次胸部放疗的调强放疗与同步整合加量调强放疗联合化疗治疗局限期小细胞肺癌的倾向性评分匹配分析

Twice-daily thoracic radiotherapy by intensity-modulated radiation therapy (IMRT) compared with simultaneous integrated boost IMRT (SIB-IMRT) with concurrent chemotherapy for patients with limited-stage small cell lung cancer. A propensity-score matched analysis.
PubMed 文献 · Radiother Oncol · 2022-01-29

该回顾性研究纳入2009年12月至2017年12月接受每日两次胸部放疗联合化疗的局限期小细胞肺癌患者112例,按放疗剂量分为IMRT组(PTV 45 Gy)和SIB-IMRT组(GTV 57 Gy、CTV 51 Gy、PTV 45 Gy),经1:1倾向性评分匹配后每组各37例。SIB-IMRT组中位无进展生存期较IMRT组延长(34.92个月 vs 17.54个月,P=0.047),但中位总生存期无显著差异(63.41个月 vs 38.52个月,P=0.261)。作者认为SIB-IMRT高剂量每日两次胸部放疗可能改善无进展生存期且未增加毒性,但未能转化为总生存获益。

要点

  • SIB-IMRT组中位无进展生存期34.92个月,IMRT组17.54个月,P=0.047。
  • 两组中位总生存期分别为63.41个月和38.52个月,P=0.261,无显著差异。
  • 作者认为SIB-IMRT可能改善无进展生存期且未增加毒性,但未带来总生存获益。

核心结论

  • 与IMRT相比,SIB-IMRT高剂量每日两次胸部放疗联合化疗用于局限期小细胞肺癌患者可能改善无进展生存期且未增加毒性,但无进展生存期的改善未能带来显著的总生存优势。

研究设计与样本

  • 回顾性分析2009年12月至2017年12月接受每日两次胸部放疗联合化疗的局限期小细胞肺癌患者临床记录,共纳入112例,IMRT组71例、SIB-IMRT组41例,采用1:1倾向性评分匹配平衡可观察的潜在混杂因素,匹配后每组各37例,主要终点为无进展生存期。

主要发现

  • 匹配后IMRT组中位无进展生存期为17.54个月,SIB-IMRT组为34.92个月(P=0.047)。
  • 匹配后IMRT组中位总生存期为38.52个月,SIB-IMRT组为63.41个月(P=0.261)。

关键数值与推荐

  • IMRT组处方剂量为计划靶区45 Gy。
  • SIB-IMRT组处方剂量为肿瘤大体体积57 Gy、临床靶区51 Gy、计划靶区45 Gy。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为回顾性研究。
  • 无进展生存期改善未能带来显著的总生存优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concurrent chemoradiotherapy is the standard treatment for limited-stage small-cell lung cancer patients (SCLC). However, the optimal dose and schedule of thoracic radiotherapy (TRT) has not been established. METHODS: We retrospectively reviewed the clinical records of limited-stage SCLC patients treated with twice-daily TRT and concurrent chemotherapy between December 2009 and December 2017. Patients were divided into two groups according to radiotherapy dose: the intensity modulated radiotherapy (IMRT) group [45 Gy to the planning target volume (PTV)] and the simultaneous integrated boost IMRT (SIB-IMRT) group (57 Gy to the gross tumour volume, 51 Gy to the clinical target volume, and 45 Gy to PTV). A 1:1 propensity score matching (PSM) was applied to balance the observable potential confounding factors between the two groups. Primary endpoint was progression-free survival (PFS). RESULTS: A total of 112 patients were enrolled in our study, including 71 patients in the IMRT group and 41 patients in the SIB-IMRT group. After PSM, the clinical features were well balanced between the groups, including 37 patients each. The median PFS was 17.54 months in the IMRT group versus 34.92 months in the SIB-IMRT group (P = 0.047). The median overall survival (OS) was 38.52 months in the IMRT group versus 63.41 months in the SIB-IMRT group (P = 0.261). CONCLUSIONS: Compared with IMRT, a high dose of twice-daily TRT by the SIB-IMRT approach with concurrent chemotherapy for limited-stage SCLC patients may improve PFS without increasing toxicities. However, PFS improvement failed to result in significant advantages in OS.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Sun H, Liu C, Zhang J, et al. Twice-daily thoracic radiotherapy by intensity-modulated radiation therapy (IMRT) compared with simultaneous integrated boost IMRT (SIB-IMRT) with concurrent chemotherapy for patients with limited-stage small cell lung cancer. A propensity-score matched analysis. Radiother Oncol. 2022. PMID: 35101460. doi:10.1016/j.radonc.2022.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。